This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Subscribe To Our Newsletter & Stay Updated
